Johnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New R&D Company
From Escp Europe Finance Society, The biggest European drugs takeover in 13 years: Johnson & Johnson has unveiled its intention to acquire the Swiss drug-maker Actelion Ltd (SIX:ATLN) with a move that will cost $30bn to the US company. Find out in this article more about the two companies, the deal structure and discover an overview of the healthcare M&A sector.
Johnson & Johnson (NYSE:JNJ), the world’s largest healthcare holding company, with total registered worldwide sales of $71.89bn in 2016, has unveiled its intention to acquire the Swiss drug-maker Actelion Ltd (SIX:ATLN) with a move that will cost $30bn to the US company.
Johnson & Johnson
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. It has more than 250 companies located in 60 countries around the world while their products are sold in over 175 countries. Their companies are broken down into several business segments: consumer healthcare, medical devices and pharmaceuticals. Johnson & Johnson’s consumer healthcare segment produces a variety of consumer care products in the areas of baby care, skin and hair care, wound care, oral health, OTC medicines and nutritionals.
Johnson & Johnson’s brands include numerous household names of medications and first aid supplies.
Among its well-known consumer products are the Band-Aid Brand line…
View original post 1,793 more words
Posted on March 23, 2017, in Uncategorized. Bookmark the permalink. Leave a comment.
Leave a comment